Loading
This study tests a PARP inhibitor; the registry reports that it is unknown.
The registry lists NCT06308406 as unknown, last updated 2024-04-11. Enrolment is 54 planned participants, an estimate. Interventions: Bevacizumab； HRS-1167. Primary measures include The number of subjects with dose-limiting toxicity (DLT); Determination of Recommended Phase II dose (RP2D). No results are posted in the registry; this does not exclude separate publications.
Shares PARP, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/